{"id":"https://openalex.org/W4362494710","doi":"https://doi.org/10.1158/1535-7163.22504077","title":"Supplementary Figures 1 through 6 from Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma","display_name":"Supplementary Figures 1 through 6 from Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362494710","doi":"https://doi.org/10.1158/1535-7163.22504077"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.22504077","doi":"https://doi.org/10.1158/1535-7163.22504077","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22504077","pdf_url":"https://aacr.figshare.com/ndownloader/files/39963534","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/ndownloader/files/39963534","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100346105","display_name":"Jin Wang","orcid":"https://orcid.org/0000-0001-5420-5704","observed_orcids":["https://orcid.org/0000-0001-5420-5704"]},"institutions":[{"id":"https://openalex.org/I160606119","display_name":"University of Tennessee Health Science Center","ror":"https://ror.org/0011qv509","country_code":"US","type":"education","lineage":["https://openalex.org/I160606119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jin Wang","raw_affiliation_strings":["Department of Pharmaceutical Sciences, College of Pharmacy. The University of Tennessee Health Science Center, Memphis, TN 38163","Room 327B, 847 Monroe Ave, Memphis, TN 38163"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, College of Pharmacy. The University of Tennessee Health Science Center, Memphis, TN 38163","institution_ids":["https://openalex.org/I160606119"]},{"raw_affiliation_string":"Room 327B, 847 Monroe Ave, Memphis, TN 38163","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100410492","display_name":"Jianjun Chen","orcid":"https://orcid.org/0000-0001-5668-6572","observed_orcids":["https://orcid.org/0000-0001-5668-6572"]},"institutions":[{"id":"https://openalex.org/I160606119","display_name":"University of Tennessee Health Science Center","ror":"https://ror.org/0011qv509","country_code":"US","type":"education","lineage":["https://openalex.org/I160606119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jianjun Chen","raw_affiliation_strings":["Department of Pharmaceutical Sciences, College of Pharmacy. The University of Tennessee Health Science Center, Memphis, TN 38163","Room 327B, 847 Monroe Ave, Memphis, TN 38163"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, College of Pharmacy. The University of Tennessee Health Science Center, Memphis, TN 38163","institution_ids":["https://openalex.org/I160606119"]},{"raw_affiliation_string":"Room 327B, 847 Monroe Ave, Memphis, TN 38163","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077433493","display_name":"Duane D. Miller","orcid":"https://orcid.org/0000-0002-2638-866X","observed_orcids":["https://orcid.org/0000-0002-2638-866X"]},"institutions":[{"id":"https://openalex.org/I160606119","display_name":"University of Tennessee Health Science Center","ror":"https://ror.org/0011qv509","country_code":"US","type":"education","lineage":["https://openalex.org/I160606119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Duane D. Miller","raw_affiliation_strings":["Department of Pharmaceutical Sciences, College of Pharmacy. The University of Tennessee Health Science Center, Memphis, TN 38163","Room 327B, 847 Monroe Ave, Memphis, TN 38163"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, College of Pharmacy. The University of Tennessee Health Science Center, Memphis, TN 38163","institution_ids":["https://openalex.org/I160606119"]},{"raw_affiliation_string":"Room 327B, 847 Monroe Ave, Memphis, TN 38163","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100318325","display_name":"W\u011bi Li","orcid":"https://orcid.org/0000-0002-9522-4474","observed_orcids":["https://orcid.org/0000-0002-9522-4474","https://orcid.org/0000-0003-4136-3409","https://orcid.org/0009-0009-9141-6389"]},"institutions":[{"id":"https://openalex.org/I160606119","display_name":"University of Tennessee Health Science Center","ror":"https://ror.org/0011qv509","country_code":"US","type":"education","lineage":["https://openalex.org/I160606119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wei Li","raw_affiliation_strings":["Department of Pharmaceutical Sciences, College of Pharmacy. The University of Tennessee Health Science Center, Memphis, TN 38163","Room 327B, 847 Monroe Ave, Memphis, TN 38163"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, College of Pharmacy. The University of Tennessee Health Science Center, Memphis, TN 38163","institution_ids":["https://openalex.org/I160606119"]},{"raw_affiliation_string":"Room 327B, 847 Monroe Ave, Memphis, TN 38163","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I160606119"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":0.9079999923706055},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.7799999713897705},{"id":"https://openalex.org/keywords/braf-v600e-melanoma","display_name":"BRAF V600E melanoma","score":0.968999981880188},{"id":"https://openalex.org/keywords/tubulin-polymerization-inhibitors","display_name":"tubulin polymerization inhibitors","score":0.9330000281333923},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.9100000262260437},{"id":"https://openalex.org/keywords/pi3k-akt-signaling","display_name":"PI3K/Akt signaling","score":0.9459999799728394},{"id":"https://openalex.org/keywords/microtubule-polymerization","display_name":"microtubule assembly","score":0.7850000262260437},{"id":"https://openalex.org/keywords/a375-cells","display_name":"A375 cells","score":0.7689999938011169},{"id":"https://openalex.org/keywords/cell-cycle","display_name":"cell cycle","score":0.7910000085830688}],"concepts":[{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.9882722496986389},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5601316690444946},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5112395286560059},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.47253966331481934},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.39780545234680176},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3948894143104553},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.380179226398468},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.27979254722595215},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.08921858668327332},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.07876923680305481}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.22504077","doi":"https://doi.org/10.1158/1535-7163.22504077","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22504077","pdf_url":"https://aacr.figshare.com/ndownloader/files/39963534","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1535-7163.22504077.v1","doi":"https://doi.org/10.1158/1535-7163.22504077.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22504077.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22504077","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figures_1_through_6_from_Synergistic_Combination_of_Novel_Tubulin_Inhibitor_ABI-274_and_Vemurafenib_Overcomes_Vemurafenib_Acquired_Resistance_in_BRAF_sup_V600E_sup_Melanoma/22504077","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.22504077","doi":"https://doi.org/10.1158/1535-7163.22504077","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22504077","pdf_url":"https://aacr.figshare.com/ndownloader/files/39963534","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4362494710.pdf","grobid_xml":"https://content.openalex.org/works/W4362494710.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362494862","https://openalex.org/W2140822400","https://openalex.org/W1554652277","https://openalex.org/W2472423380","https://openalex.org/W3142095748","https://openalex.org/W2171108516","https://openalex.org/W2922270413","https://openalex.org/W3000104628","https://openalex.org/W2344670011","https://openalex.org/W2475168395"],"abstract_inverted_index":{"PDF":[0],"-":[1],"476K,":[2],"Figure":[3,30,46,63,84,102],"S1.":[4],"Establishment":[5],"of":[6,28,55,75,80,87],"vemurafenib-resistant":[7,44,111],"A375":[8,16,59,109],"melanoma":[9],"cell":[10,17,40],"line":[11,18],"A375RF21":[12,61,70,113],"from":[13],"its":[14],"parental":[15],"using":[19],"chronic":[20],"selection":[21],"over":[22],"3":[23],"months":[24],"with":[25],"increasing":[26],"concentrations":[27],"vemurafenib;":[29],"S2.":[31],"Anti-phospho-histone":[32],"H3":[33],"and":[34,60,77,90,110],"PI":[35],"(propidium":[36],"iodide)":[37],"bivariate":[38],"staining":[39],"cycle":[41],"analysis":[42],"on":[43,93],"cells;":[45,62],"S3.":[47],"In":[48,104],"vitro":[49,105],"dose-response":[50],"curves":[51],"(n":[52,99],"=":[53,100],"5)":[54],"each":[56],"combination":[57,91],"in":[58,69],"S4.":[64],"Major":[65],"vemurafenib":[66],"resistance":[67],"mechanisms":[68],"cells":[71],"are":[72],"the":[73,78,81],"over-expression":[74],"PDGF\u03b2":[76],"activations":[79],"PI3K-AKT":[82],"pathway;":[83],"S5.":[85],"Effect":[86],"single":[88],"agent":[89],"treatment":[92],"purified-protein":[94],"based":[95],"tubulin":[96],"polymerization":[97],"assay":[98],"3);":[101],"S6.":[103],"growth":[106],"curve":[107],"for":[108],"subline":[112],"cells.":[114]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}